Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegvorhyaluronidase alfa + cisplatin + gemcitabine
- Development stage
- Unknown
- Lead developer
- Halozyme
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous
01
Overview
This is a **combination regimen** consisting of pegvorhyaluronidase alfa—a pegylated recombinant human hyaluronidase enzyme that degrades hyaluronan in the tumor microenvironment—and two chemotherapeutic small molecules, cisplatin and gemcitabine. Pegvorhyaluronidase alfa is designed to break down hyaluronan, a supportive extracellular matrix component frequently overexpressed in certain tumors such as pancreatic ductal adenocarcinoma; by degrading hyaluronan, it improves tumor perfusion and the delivery of chemotherapeutic agents. Cisplatin is a platinum-based DNA-damaging agent, and gemcitabine is a nucleoside analog that inhibits DNA synthesis. This combination is being explored for its potential to enhance chemotherapy efficacy in solid tumors with dense stroma, although most clinical evaluation has centered on pegvorhyaluronidase alfa with gemcitabine (± nab-paclitaxel), with limited published clinical data available specifically for the cisplatin-including triple regimen[1][2][4].
- Other names
- pegvorhyaluronidase alfa + cisplatin + gemcitabine
02
Targets
DNA polymerase familyDNARNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on pegvorhyaluronidase alfa + cisplatin + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegvorhyaluronidase alfa + cisplatin + gemcitabine.